Quantcast
Last updated on April 18, 2014 at 11:23 EDT

Latest Multiple myeloma Stories

2013-08-19 08:28:31

SUSTAIN study to investigate the potential of a chronic SelG1 therapy to reduce or prevent the occurrence of sickle cell-related pain crises OKLAHOMA CITY, Aug. 19, 2013 /PRNewswire/ -- Selexys Pharmaceuticals Corporation, a privately held biopharmaceutical company that is developing therapies to treat inflammatory and thrombotic diseases, today announced that enrollment has been initiated in SUSTAIN, a Phase II, multicenter, randomized, placebo-controlled, double-blind, 12-month...

2013-07-22 23:24:22

The update will result in improved patient prognoses, better informed patient care decisions and reduced costs. (PRWEB) July 22, 2013 Signal Genetics today announced that it has launched an update to its MyPRS gene expression assay for patients with Multiple Myeloma, which will improve patient prognoses, enable better informed patient care decisions, and ultimately reduce costs. Every MyPRS test performed now includes an analysis of an additional set of 813-genes within the patient’s...

2013-07-01 12:28:33

WHITE PLAINS, N.Y., July 1, 2013 /PRNewswire/ -- The Leukemia & Lymphoma Society (LLS) today announced a collaboration with Johns Hopkins University School of Medicine to advance a novel adoptive immunotherapy for patients with poor prognosis myeloma, a blood cancer. The approach shows promise for patients with other blood cancers as well. Under the leadership of Ivan Borrello, M.D., Johns Hopkins Kimmel Cancer Center, a team of researchers is testing a method using...

2013-06-27 23:34:00

Cancer Support Community's expanded Cancer Experience Registry created to identify social and emotional needs of people living with multiple myeloma Washington, D.C. (PRWEB) June 27, 2013 The Cancer Support Community’s Research and Training Institute has added a focus on people living with multiple myeloma to its nationwide Registry today. According to the National Cancer Institute, there will be 22,350 new cases of multiple myeloma diagnosed in the U.S. this year. This type of...

2013-06-20 16:27:14

SUNNYVALE, Calif., June 20, 2013 /PRNewswire/ -- Pharmacyclics, Inc. (the "Company") (Nasdaq: PCYC) today announced results of a study evaluating ibrutinib, an investigational oral Bruton's tyrosine kinase (BTK) inhibitor in patients with Waldenstrom's Macroglobulinemia (WM). Pharmacyclics is jointly developing ibrutinib with Janssen Research & Development, LLC. The data were presented today at the International Conference on Malignant Lymphoma (ICML), taking place in Lugano,...

2013-06-20 00:21:44

SUNNYVALE, Calif., June 19, 2013 /PRNewswire/ -- Pharmacyclics, Inc. (the "Company") (Nasdaq: PCYC) today announced that The New England Journal of Medicine (NEJM) published results of a Phase 2 study evaluating the investigational oral Bruton's tyrosine kinase (BTK) inhibitor ibrutinib in patients with relapsed/refractory mantle cell lymphoma (MCL) online. These data suggested ibrutinib may be effective and generally well-tolerated in patients with relapsed/refractory MCL. Results of a...

2013-06-17 08:28:07

BOULDER, Colo., June 17, 2013 /PRNewswire/ -- Array BioPharma Inc. (NASDAQ: ARRY) today announced that interim results from an ongoing ARRY-520 clinical trial in multiple myeloma (MM) were presented at the 2013 Congress of the European Hematology Association in Stockholm, Sweden. Also at the meeting, Array presented updated information on a potential patient selection marker for ARRY-520. ARRY-520 is a highly selective, targeted inhibitor of KSP with a mechanism of action distinct...

2013-06-11 15:04:44

Research compares standard treatment and addition of targeted therapy with radiolabeled antibodies that track and kill lymphoma cancer cells A new patient protocol for aggressive and recurrent lymphoma that combines intensive chemotherapy and radioimmunotherapy (RIT) may become the most powerful cancer-killing therapy available, with the hope that patients´ lymphoma can be eradicated as they prepare for bone marrow transplant, say researchers at the 2013 Annual Meeting of the Society...

2013-06-05 16:24:36

WHITE PLAINS, N.Y., June 5, 2013 /PRNewswire/ -- Today's U.S. Food and Drug Administration (FDA) approval of lenalidomide (Revlimid®) to treat patients with mantle cell lymphoma (MCL) is encouraging news for these patients. "Despite advances in treatment, most mantle cell lymphoma patients relapse over time. So, lenalidomide is a welcome effective treatment option for these patients," said Clare Karten, senior director of mission education for The Leukemia & Lymphoma Society (LLS)....

2013-05-28 08:29:22

Company Plans to Allocate Funds for Investigation into Methods in Genomics to Predict Multiple Myeloma Patient Response to Therapeutic Treatments BUFFALO, N.Y., May 28, 2013 /PRNewswire/ -- Empire Genomics, LLC (www.empiregenomics.com) has been awarded a Phase I SBIR Grant by the National Institute of Health/National Cancer Institute to develop a genomic companion diagnostic test for multiple myeloma (MM). This is the first SBIR grant Empire Genomics has been awarded and it will be...